Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.

Noriko FukuharaKoji KatoHideki GotoTajima TakeshiMayu KawaguchiKota TokushigeKoichi AkashiTakanori TeshimaHideo HarigaeStephen J SchusterCatherine ThieblemontMartin DreylingNathan Fowler

Published in: International journal of hematology (2022)

Tisagenlecleucel showed high efficacy and manageable safety in adult Japanese patients with r/r FL. Moreover, the clinical outcomes were similar to the global population, which supports the potential of tisagenlecleucel in Japanese patients with r/r FL.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
phase iii
randomized controlled trial
phase ii
human health
climate change